Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 2Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 5Neoplasm Metastasis 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Carcinoma, Renal Cell 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Trastuzumab 61Paclitaxel 57Cyclophosphamide 44pembrolizumab 35Fulvestrant 34Capecitabine 29Carboplatin 27Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 14durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × bicalutamide × Clear all
NCT05095207 2026-04-13

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Recruiting
42 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02605486 2025-07-03

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
46 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡